Germany Archives

News and Trends 16 Apr 2015

flash4science, the life science private shopping club

Any scientist knows how expensive purchasing new equipment can be. However, one platform, flash4Science, in particular caught our attention. The company located in Germany has set itself an interesting challenge as it tries to combine life sciences and private shopping together. Two domains, which, on paper, seem completely incompatible! It is the world’s first biotech […]

April 16, 2015 - 2 minutesmins - By Alexandre Lowrey

News and Trends 9 Apr 2015

Ipsen and Hannover Medical School start joint research in Recombinant Botulinum Neurotoxins

Ipsen and Hannover Medical School, one of the world’s leading university medical centres, have entered into a joint research collaboration agreement, signed in last September. Their objective is to develop new therapeutics for patients with serious neurological, endocrinological or oncological disease. The research program aims at testing recombinant botulinum neurotoxin proteins to affect intracellular molecular […]

April 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 7 Apr 2015

Open Bionics, lending a 3D-Printed helping hand

Little could the young Joel Gibbard have ever imagined that those Meccano games he once used to play with as a child, would one day lead him to become Britain’s Design Engineer of the Year amongst other prestigious awards. Open Bionics, the Bristol-based company he founded, aims at providing low-cost robotic hands. I got to […]

April 7, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 31 Mar 2015

Merck Serono and Intrexon, to develop CAR-T Therapy

Merck Sereno, the biopharmaceutical business of Merck, and the synthetic biology leader Intrexon announced yesterday an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, […]

March 31, 2015 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Mar 2015

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first genetically-engineered cell therapy. The ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, will take place at the Klinikum Grosshadern in Munich. This is the first time that a genetically engineered Mesenchymal Stem Cell […]

March 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Mar 2015

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence to Minimally Invasive Testing) for Epi proColon, its non-invasive blood-based test for colorectal cancer (CRC) screening. Epigenomics has successfully completed enrollment in the ADMIT clinical trial this week. Study subjects were identified as historically non-compliant to CRC screening according to […]

March 25, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 24 Mar 2015

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new investment brings the total Series A to €14.2M to the biopharmaceutical company that is developing RNA-based immunotherapeutics for the treatment of […]

March 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 23 Mar 2015

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

University of Copenhagen released a vaccine candidate against the form of malaria that strikes pregnant women, for testing in humans. The vaccine candidate contains a malaria antigen made with ExpreS2ion Biotechnologies’ protein expression technology, ExpreS2. This vaccine candidate results from many years of research done by Professor Ali Salanti and his team at the Department […]

March 23, 2015 - 2 minutesmins - By Lourdes Riquelme

New oncology neoliquid neoplus cancer diagnosis

News and Trends 17 Mar 2015

New Oncology finances its Genetic Test for Cancer Diagnosis

New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumor DNA (ctDNA) of cancer patients. New Oncology’s pan-cancer diagnostic platform NEOplus reliably detects actionable genome alterations from one single patient sample with short turn-around times. In contrast to […]

March 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 14 Mar 2015

Promising Collaboration Between Evotec and Second Genome

Evotec AG and Second Genome decided to collaborate in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be […]

March 14, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 11 Mar 2015

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

Today, it has been accepted! The first drug approved through the Early Access to Medicine Scheme (EAMS), named pembrolizumab, is an immunotherapy treatment for advanced melanoma. The treatment has been developed by Merck, known as MSD outside the United States and Canada, with early development work carried out using MRC Technology’s antibody humanization expertise. EAMS is […]

March 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 9 Mar 2015

MorphoSys and Emergent BioSolutions Initiate Phase I

MorphoSys AG and Emergent BioSolutions will initiate a Phase I clinical study to evaluate the safety, tolerability, and clinical activity of MOR209/ES414 in patients with metastatic castration-resistant prostate cancer (mCRPC). A few months ago, we talked about the beginning of the collaboration between MorphoSys and Emergent BioSolutions. Now, the fruit of their combined work, an […]

March 9, 2015 - 3 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Germany

flash4science, the life science private shopping club

Ipsen and Hannover Medical School start joint research in Recombinant Botulinum Neurotoxins

Open Bionics, lending a 3D-Printed helping hand

Merck Serono and Intrexon, to develop CAR-T Therapy

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

A Vaccine against Placental Malaria made with ExpreS2ion’s Protein Expression Technology

New Oncology finances its Genetic Test for Cancer Diagnosis

Promising Collaboration Between Evotec and Second Genome

First Treatment Approved under Early Access to Medicine Scheme (EAMS)

MorphoSys and Emergent BioSolutions Initiate Phase I

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!